Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19-UCART in Relapsed or Refractory B-cell Malignancies
NCT03229876Phase 1Suspended
- Sponsor
- BRL Medicine Inc.
- Start
- Jun 2019
- Primary completion
- Dec 2023
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BRL-301 in acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL), sponsored by BRL Medicine Inc. Primary endpoint: Dose Limiting Toxicities occurrence at 35 days. Started Jun 2019; status: suspended.
02
Drugs
BRL-301
03
Conditions
acute lymphoblastic leukemia (ALL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT03229876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03229876.